ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Kansas » Hematology Oncology

Top Hematology Oncology Prescribers in Kansas

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
FADI ESTEPHAN MD

Hematology Oncology

3,354

$514K

402
352 are 65+

6%
patients receiving schedule two controlled substances

Avg: 12%

12%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 15%

$153
Average prescription price

Avg: $397

BASSAM MATTAR MD

Hematology Oncology

2,799

$800K

342
287 are 65+

8%
patients receiving schedule two controlled substances

Avg: 12%

19%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 15%

$286
Average prescription price

Avg: $397

SHAKER DAKHIL MD

Hematology Oncology

2,769

$1.11M

368
308 are 65+

8%
patients receiving schedule two controlled substances

Avg: 12%

19%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 15%

$400
Average prescription price

Avg: $397

PAVAN REDDY M.D.

Hematology Oncology

2,701

$613K

319
258 are 65+

14%
patients receiving schedule two controlled substances

Avg: 12%

15%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$227
Average prescription price

Avg: $397

PHU TRUONG MD

Hematology Oncology

2,054

$586K

249
210 are 65+

12%
patients receiving schedule two controlled substances

Avg: 12%

22%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$285
Average prescription price

Avg: $397

NASSIM NABBOUT M.D.

Hematology Oncology

2,005

$1.37M

271
210 are 65+

11%
patients receiving schedule two controlled substances

Avg: 12%

16%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 15%

$683
Average prescription price

Avg: $397

MICHAEL CANNON MD

Hematology Oncology

1,801

$1.29M

230
189 are 65+

10%
patients receiving schedule two controlled substances

Avg: 12%

15%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 15%

$719
Average prescription price

Avg: $397

MATTHEW STEIN M.D.

Hematology Oncology

1,695

$756K

133
109 are 65+

20%
patients receiving schedule two controlled substances

Avg: 12%

13%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

23%
prescriptions for brand name drugs

Avg: 15%

$446
Average prescription price

Avg: $397

DENNIS MOORE MD

Hematology Oncology

1,586

$693K

243
210 are 65+

12%
patients receiving schedule two controlled substances

Avg: 12%

17%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$437
Average prescription price

Avg: $397

MICHAEL HURWITZ MD

Hematology Oncology

1,324

$183K

196
167 are 65+

10%
patients receiving schedule two controlled substances

Avg: 12%

15%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$138
Average prescription price

Avg: $397

BOBAN MATHEW M.D.

Hematology Oncology

1,284

$833K

138
108 are 65+

21%
patients receiving schedule two controlled substances

Avg: 12%

12%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 15%

$649
Average prescription price

Avg: $397

DENNIS MOORE M.D.

Hematology Oncology

1,277

$489K

152
122 are 65+

13%
patients receiving schedule two controlled substances

Avg: 12%

13%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 15%

$383
Average prescription price

Avg: $397

ADRIAN CARACIONI MD

Hematology Oncology

1,276

$783K

163
137 are 65+

22%
patients receiving schedule two controlled substances

Avg: 12%

10%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 15%

$614
Average prescription price

Avg: $397

SHARON SOULE M.D.

Hematology Oncology

1,271

$244K

138
99 are 65+

19%
patients receiving schedule two controlled substances

Avg: 12%

11%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 15%

$192
Average prescription price

Avg: $397

DAVID EINSPAHR M.D.

Hematology Oncology

1,250

$1.21M

167
137 are 65+

8%
patients receiving schedule two controlled substances

Avg: 12%

14%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

24%
prescriptions for brand name drugs

Avg: 15%

$968
Average prescription price

Avg: $397

LARRY BECK M.D.

Hematology Oncology

1,234

$943K

149
131 are 65+

9%
patients receiving schedule two controlled substances

Avg: 12%

9%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 15%

$764
Average prescription price

Avg: $397

QAMAR KHAN M.D.

Hematology Oncology

1,203

$353K

178
130 are 65+

12%
patients receiving schedule two controlled substances

Avg: 12%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 15%

$294
Average prescription price

Avg: $397

SETH PAGE M.D.

Hematology Oncology

1,172

$398K

149
116 are 65+

17%
patients receiving schedule two controlled substances

Avg: 12%

15%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 15%

$340
Average prescription price

Avg: $397

JOSEPH MCGUIRK D.O.

Hematology Oncology

891

$278K

113
61 are 65+

36%
patients receiving schedule two controlled substances

Avg: 12%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

21%
prescriptions for brand name drugs

Avg: 15%

$312
Average prescription price

Avg: $397

PETER VAN VELDHUIZEN M.D.

Hematology Oncology

843

$617K

112
86 are 65+

25%
patients receiving schedule two controlled substances

Avg: 12%

17%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 15%

$732
Average prescription price

Avg: $397

JOSEPH STILWILL MD

Hematology Oncology

839

$234K

130
113 are 65+

12%
patients receiving schedule two controlled substances

Avg: 12%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 15%

$279
Average prescription price

Avg: $397

MOUHAMMED KYASA MD

Hematology Oncology

820

$229K

125
100 are 65+

16%
patients receiving schedule two controlled substances

Avg: 12%

10%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$279
Average prescription price

Avg: $397

AMY RABE M.D.

Hematology Oncology

819

$123K

137
114 are 65+

0%
patients receiving schedule two controlled substances

Avg: 12%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 15%

$150
Average prescription price

Avg: $397

MICHELLE AFFIELD MD

Hematology Oncology

816

$75K

106
78 are 65+

26%
patients receiving schedule two controlled substances

Avg: 12%

19%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

7%
prescriptions for brand name drugs

Avg: 15%

$92
Average prescription price

Avg: $397

PRAKASH NEUPANE M.D.

Hematology Oncology

782

$103K

119
72 are 65+

29%
patients receiving schedule two controlled substances

Avg: 12%

10%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 15%

$132
Average prescription price

Avg: $397

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank